Safety and efficacy of FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab as second line Therapy in Advanced colorectal Cancer previously treated with bevacizumab.

ABSTRACT: Interventions: FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab is treated until progression. Primary outcome(s): progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2617856 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR